摘要
本院3例晚期重症支气管肺泡癌患者经新型靶向制剂表皮生长因子酪氨酸激酶抑制剂Gefitinib(Iressa)治疗取得显著疗效,提示Gefitinib可有效治疗晚期经含有铂类和/或泰索帝(TXT)治疗失败的细支气管肺泡癌及一般情况差、无法化疗的患者。
We described 3 cases of advanced bronchioloalveolar carcinoma(BAC), in whom once-daily treatment with 250 mg Gefitinib(Iressa)demonstrated remarkable antitumor effects. Gefitinib may produce dramatic clinical responses when admi-nistered to patients with poor performance status who had received heavy platinum/docetaxel-based prior chemotherapy.
出处
《中国医学科学院学报》
CAS
CSCD
北大核心
2004年第3期340-343,共4页
Acta Academiae Medicinae Sinicae
关键词
表皮生长因子受体肺肿瘤
化学治疗
epidermal growth factor receptor
pulmonary neoplasma
chemotherapy
